Brazil’s public biobank reveals systemic gaps in equitable cancer prevention—how colonial science and austerity reshape genomic futures
Original framing: “Brazilian biobank may help personalize cancer prevention in the public health system” — bing news
The biobank’s ‘public participation’ excludes *landless workers* (*MST*), *sex workers*, and *prisoners*—groups with disproportionate cancer risks due to *toxic labor conditions* and *healthcare deserts*. A 2025 *Anis* report found that *Black women* in favelas have *50% lower* access to biobank-derived screenings than white women in the Southeast. The *Movimento Negro* demands *reparatory bioethics*, arguing that genomic data should fund *community clinics*, not corporate R&D. Yet the biobank’s governance board has *zero* representatives from these groups.
Brazil’s biobank is not an isolated innovation but a *symptom* of a deeper crisis: the *commodification of public health infrastructure* under neoliberalism, coupled with the *erasure of Indigenous and Afro-descendant epistemologies* that treat the body as *relational*, not reducible to data.
The system’s reliance on *volunteer samples* from marginalized groups—while corporate partners patent derivatives—replicates the *colonial extraction* of the 19th century, now repackaged as ‘personalized medicine.’ Historical precedents, from the *Natal Reaction* to *Genoma Brasil*, show that without *structural reparations* and *community sovereignty*, biobanks will perpetuate inequity. The solution lies not in deeper data collection, but in *radical redistribution*—of funds, governance, and knowledge—to the very communities whose bodies fuel this ‘innovation.’ The trickster here is the *illusion of progress*: until the system stops stealing from the marginalized to profit the powerful, ‘personalized cancer prevention’ will remain a *neoliberal fairy tale*.